Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Mizuho Medy Co's annualizedNet Income for the quarter that ended in Dec. 2025 was 円0 Mil.
Mizuho Medy Co's average Total Assets over the quarter that ended in Dec. 2025 was 円20,985 Mil. Therefore, Mizuho Medy Co's annualized ROA % for the quarter that ended in Dec. 2025 was 0.00%.
The historical rank and industry rank for Mizuho Medy Co's ROA % or its related term are showing as below:
TSE:4595'
s ROA % Range Over the Past 10 Years
Min: 4.11 Med: 17.18 Max: 52.8
Current: 4.11
During the past 12 years, Mizuho Medy Co's highest ROA % was 52.80%. The lowest was 4.11%. And the median was 17.18%.
TSE:4595's ROA % is ranked better than 56.6% of 1007
companies
in the Drug Manufacturers industry
Industry Median: 2.78
vs TSE:4595: 4.11
Mizuho Medy Co (TSE:4595) ROA % Explanation
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is four times the quarterly (Dec. 2025) net income data. The Revenue data used here is four times the quarterly (Dec. 2025) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
Mizuho Medy Co ROA % Related Terms
Mizuho Medy Co ROA % Historical Data
* Premium members only.
The historical data trend for Mizuho Medy Co's ROA % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Mizuho Medy Co's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mizuho Medy Co ROA % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Mizuho Medy Co's ROA % distribution charts can be found below:
* The bar in red indicates where Mizuho Medy Co's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Dec. 2025) net income data.
ROA % is displayed in the 30-year financial page.
Mizuho Medy Co (TSE:4595) has a ROA % of 0.00% as of Dec. 2025. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Mizuho Medy Co and its competitors. Over the past decade, Mizuho Medy Co's ROA % has ranged from 4.11 to 52.80. According to the industry distribution chart, Mizuho Medy Co ranks #437 out of 1007 companies in the Drug Manufacturers industry, placing it in the top 43.4%.
Is Mizuho Medy Co's ROA % too high?
Mizuho Medy Co's current ROA % is 0.00%. Over the past 10 years, this metric has ranged from a low of 4.11 to a high of 52.80. Based on the distribution chart, Mizuho Medy Co ranks #437 out of 1007 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Mizuho Medy Co has a GF Score™ of 84/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Mizuho Medy Co's ROA % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Mizuho Medy Co ranks #437 out of 1007 companies for ROA %. This puts Mizuho Medy Co in the upper half of its industry. The industry median ROA % is 2.78. Historically, Mizuho Medy Co's own ROA % has ranged from 4.11 to 52.80 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Drug Manufacturers company?
The median ROA % among Drug Manufacturers companies is 2.78, based on 1,007 companies in the industry. Companies in the top quartile (top 25%) have a ROA % significantly above this median, while those in the bottom quartile fall well below. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Mizuho Medy Co and its competitors. For the Drug Manufacturers industry, the median ROA % is 2.78 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mizuho Medy Co's current ROA % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mizuho Medy Co stock overvalued right now?
Based on GuruFocus' analysis, Mizuho Medy Co (TSE:4595) is currently considered Modestly Overvalued. The stock's GF Value™ is 円1,440.52, compared to a current price of 円1,662.00 — trading 15.4% above its estimated fair value. The current ROA % is 0.00%. Mizuho Medy Co's overall GF Score™ is 84/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Mizuho Medy Co (TSE:4595), the current ROA % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mizuho Medy Co (TSE:4595) Overvalued in 2026?
Based on GuruFocus' analysis, Mizuho Medy Co stock appears to be overvalued.
The current stock price of 円1,662.00 is trading 15.4% above its estimated GF Value™ of 円1,440.52.
GuruFocus considers Mizuho Medy Co to be Modestly Overvalued.
Key valuation signals for TSE:4595:
ROA %: 0.00%
GF Value™: 円1,440.52 vs. price of 円1,662.00 (15.4% above fair value)
No single metric tells the full story. See the TSE:4595 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Mizuho Medy Co Ltd engages in research and development, manufacture, and distribution of in-vitro diagnostic products. The company provides immuno assay test products, such as influenza virus kits; Infectious diseases test kits; fecal occult blood test kits for detection of human hemoglobin and human transferrin in feces; and biochemical liquid stable reagents for professionals. It also offers HCG (midstream test), including a digital p-check test for OTC. It also offers fruit tree virus test drugs to agricultural testing places.
84GF Score
Get the complete analysis for TSE:4595
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4595 has been successfully added to your 
